Evidence map›Paper›PMID 38181746›Full record

ArticleCell stem cell2024

The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids.

Shree Bose, Xiling Shen

Abstract readNewsComment
PubMed Publisher
In one paragraph

Article in Cell stem cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Shree BoseDepartment of Internal Medicine, University of Chicago, Chicago, IL, USA.
Xiling ShenTerasaki Institute for Biomedical Innovation, Los Angeles, CA, USA. Electronic address: xiling.shen@terasaki.org.
Terasaki Foundation · USUniversity of Chicago · US

Funding

Robust Control of the Stem Cell NicheR35GM122465 · NIGMS · TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION · PI Xiling Shen · 2017 to 2026
$5.6M
Investigating the Metabolic Reprogramming of Ovarian Tumors During Omental MetastasisF30CA257365 · NCI · DUKE UNIVERSITY · PI BOSE, SHREE · 2021 to 2022
$88k
NCI NIH HHS F30 CA257365NIGMS NIH HHS R35 GM122465
6 · The paper itself

Abstract

Using an isogenic organoid platform to model pancreatic cancer, Duan et al. establish an important link between mutant KRAS and cholesterol metabolism and identify perhexiline maleate as a possible therapeutic to target this relationship.

Indexed as

Metabolic ReprogrammingPancreatic NeoplasmsHumansLipid MetabolismOrganoidsProto-Oncogene Proteins p21(ras)KRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID38181746
OpenAlexW4390589243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.